Marketing research of the domestic market of antibiotics and chemotherapeutic drugs for use in dermatology

Results. Analysis of the assortment structure of the domestic market of antibiotics and chemotherapeutic drugs for use in dermatology allowed us to establish that in this segment there are original drugs (30.4 %) and generics (69.6 %), monopreparations (84.1 %) and combined (15.9 %) ones. Drugs of the studied group are represented by various dosage forms, among which soft dosage forms dominate (85.4 %). When studying the corporate structure of this market segment, it was found that 56.6 % of drugs come from abroad from 12 countries of the world and 21 pharmaceutical companies, the leader of which is the United Kingdom (dij = 0.0758). The study of the level of competition showed that the greatest competition is observed among the manufacturers of acyclovir and mupirocin generics (Kvi = 0.89). Calculation of the liquidity ratio, which exceeds 0.5, confirms incomplete availability of these medicines for the population of Ukraine.

Актуальные вопросы фармацевтической и медицинской науки и практики. 2022. Т. 15, № 1(38). 72-79 The incidence of dermatoses today is an urgent medical and social problem not only in Ukraine, but also around the world [1]. Moreover, over the past 10 years, there has been an increase in the share of dermatological and venereal diseases in the overall structure of morbidity in our country.
Treatment of patients with skin diseases is a rather complex task, requiring, in addition to special knowledge of the essence of certain dermatoses and their causes, as well as thorough familiarity with the effect of the drugs used [2].
Skin infections are among the most common disorders found in community and hospital environments. These can present in a variety of forms, ranging from limited superficial infections that are controlled by treatment with topical antibiotics to severe infections of deep tissues that can lead to death if the patient is not appropriately treated [3].
Although the vast majority of skin infections must be treated with systemic antibiotics, topical antibiotics are used overwhelmingly in the world, often as self-prescribed medications without taking into account the sensitivity of the presumed bacteria. Dermatologists are aware that different types of topical antibiotics kill different species of bacteria and tend to be more specific in their prescriptions. At present, local antibiotics are advised to treat minor superficial uncomplicated skin infections (e.g. impetigo) and to prevent bacterial infections caused into minor cuts, scrapes, and burns [4,5].

Aim
The purpose of work is marketing research of the domestic market of antibiotics and chemotherapeutic drugs for use in dermatology.

Materials and methods
To achieve this goal, electronic official sources of information [6,8] and pharmacy websites were used [9]. Desk reaserch and selective analytical method were used.

Results
The study of the assortment structure was carried out in accordance with the "State Register of Medicines of Ukraine" (PBX code D06), which registered 69 names of medicines for topical use of these pharmacological subgroups (D06A, D06B, D06C) [6,8].
Of the studied group, 84.1 % were monopreparations and 15.9 % were combined medicines.
The results of the analysis of the corporate structure of the market segment under study are presented in Table 1. Table 1 shows that only 46.38 % of the drugs in the study group are produced on the territory of Ukraine.
53.62 % of drugs in this group come from abroad, from 12 countries from 21 pharmaceutical companies.   The leader among foreign manufacturers is the United Kingdom, whose 3 pharmaceutical companies provide 11.6 % of antibacterial and chemotherapeutic agents for the treatment of dermatological diseases to the Ukrainian market.
The share of the national pharmaceutical market segment occupied by each of the manufacturers of medicines for the treatment of dermatological diseases was calculated using the formula: where nij -is the number of drugs of the j-th company in the i-segment; Σnij -total number of segment of i-drugs registered in Ukraine.
The calculation data are shown in Table 2.
The results showed that the largest share in the study segment belongs to the pharmaceutical company Glaxo Operations UK, Limited, Great Britain (dij = 0.0758).
At the next stage, the competitiveness of firms providing medicines of the study group to the national pharmaceutical market was analyzed [7].
To determine the level of competition between manufacturers of analogue drugs, the intensity coefficient Kvi was calculated using the formula: where n -is the number of all competitive analogues produced by different manufacturers.
At the same time, the studied drugs were grouped by active substances into 18 groups for monodrugs and 7 groups for combined drugs according to the ATC classification: After analyzing the data obtained, we can conclude that the greatest competition is observed among companies that produce analogues of Acyclovir and Mupirocin (Kvi = 0.89), ( Table 3). Among the pharmaceutical companies-enter prises that produce these drugs, there are domestic ones: LLC DKP pharmaceutical factory, Ukraine; Ukrainian-Spanish joint venture "Sperco Ukraine", Ukraine; PJSC "Farmak", Ukraine; PJSC "Kyivmedpreparat", Ukraine.
A number of drugs from the groups of Tetracycline, Sodium Fusidate, Neomycin, Gentamicin, Silver Sulfatiazole, Denotivir, Glycerizic Acid, Doconazole among monopreparations and Acyclovir, Amikacin, Metronidazole, Ofloxacin have no analogues in the pharmaceutical market of Ukraine, so in this case there is no competition (Kvi = 0).
Among the studied drugs, there are original proprietary drugs. Their specific weight in a particular pharmacotherapeutic group shows how attractive this group is for research in terms of updating with new drugs. These are the so-called "Brandname".
The specific weight of branded drugs by group allows us to determine the level of monopolization of the corresponding market segments. For a comparative assessment of these indicators, the conditional coefficient of monopolization of market segments-Kµ -is used.
where Bn -number of branded drugs; ∑Nj -the total number of registered drugs in the jth pharmacotherapeutic group.
We calculated the monopolization coefficient ( Table 4). This table shows that among pharmaceutical companies supplying antibacterial and chemotherapeutic agents for the treatment of dermatological diseases, Pharma International Company, Jordan has the highest monopolization coefficient (Kµ = 0.0455).
To study the indicators of socio-economic accessibility, the liquidity ratio and the solvency adequacy ratio were determined.
The liquidity ratio was calculated using the formula: where Kliq -price liquidity ratio; Pmax -maximum price for medicines; Pmin -minimum price for the drug.